Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Capital Expenditures (2016 - 2025)

Tg Therapeutics (TGTX) has 9 years of Capital Expenditures data on record, last reported at $67000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 219.05% year-over-year to $67000.0; the TTM value through Dec 2025 reached $214000.0, up 375.56%, while the annual FY2025 figure was $214000.0, 375.56% up from the prior year.
  • Capital Expenditures reached $67000.0 in Q4 2025 per TGTX's latest filing, down from $80000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $175000.0 in Q2 2021 and bottomed at $3000.0 in Q4 2022.
  • Average Capital Expenditures over 4 years is $51846.2, with a median of $42000.0 recorded in 2025.
  • Peak YoY movement for Capital Expenditures: skyrocketed 288.89% in 2021, then plummeted 96.25% in 2022.
  • A 4-year view of Capital Expenditures shows it stood at $80000.0 in 2021, then tumbled by 96.25% to $3000.0 in 2022, then soared by 600.0% to $21000.0 in 2024, then surged by 219.05% to $67000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $67000.0 in Q4 2025, $80000.0 in Q3 2025, and $42000.0 in Q2 2025.